|
Market Closed -
Nasdaq
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 219.72 USD | -4.96% |
|
-14.16% | -44.75% |
| 09-17 | Alnylam Pharmaceuticals, Inc. - Special Call | |
| 09-14 | Alnylam Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM |
| Market Cap | 29.4B 26.12B 24.38B 22.22B 41.91B 2,826B 42.3B 295B 114B 1,445B 110B 108B 4,637B | P/E 2026 * |
33x | P/E 2027 * | 23.2x |
|---|---|---|---|---|---|
| Enterprise Value | 26.37B 23.43B 21.86B 19.93B 37.59B 2,535B 37.94B 265B 103B 1,296B 98.99B 96.84B 4,158B | EV / Sales 2026 * |
4.81x | EV / Sales 2027 * | 3.54x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALNY | Delayed | |
CBOE
| ALNY | Real-time | |
|
Tradegate
| DUL | Real-time | |
|
Boerse Muenchen
| DUL | Real-time | |
|
Deutsche Boerse AG
| DUL | Delayed | |
|
Xetra
| DUL | End-of-day quote | |
|
Berne S.E.
| DUL | End-of-day quote | |
|
London S.E.
| 0HD2 | Delayed | |
|
Mexican S.E.
| ALNY * | End-of-day quote | |
|
Börse Stuttgart
| DUL | Delayed | |
|
Borsa Italiana
| 1ALNY | End-of-day quote | |
|
Wiener Boerse
| ALNY | End-of-day quote |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | -4.96% | ||
| 1 week | -14.16% | ||
| Current month | -10.95% | ||
| 1 month | -16.93% | ||
| 3 months | -29.75% | ||
| 6 months | -31.09% | ||
| Current year | -44.75% |
| 1 week | 219.4 |  | 257.27 |
| 1 month | 219.4 | | 272.08 |
| Current year | 197.81 | | 427.05 |
| 1 year | 197.81 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2021-12-31 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 2019-08-12 |
| Chief Tech/Sci/R&D Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 2012-04-22 |
Amy Schulman
CHM | Chairman | 65 | 2023-01-04 |
David Pyott
BRD | Director/Board Member | 72 | 2015-12-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/19/26 | Free | Chief Executive Officer | 107 | 0.0001% | ||
| 6/1/26 | Exercice | Director | 11,490 | 0.0086% | ||
| 6/1/26 | Free | Director | 4,393 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.96% | -14.16% | -51.85% | +27.07% | 29.4B | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -1.18% | -4.47% | +18.28% | +55.72% | 372.66B | |
| Weighted average by Cap. | -0.63% | -3.41% | +28.43% | +70.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.48B 4.87B 4.55B 4.14B 7.81B 527B 7.89B 55.01B 21.32B 269B 20.58B 20.13B 865B | 6.94B 6.17B 5.76B 5.25B 9.9B 668B 9.99B 69.69B 27.01B 341B 26.07B 25.51B 1,095B |
| Net income | 900M 800M 747M 681M 1.28B 86.56B 1.3B 9.04B 3.5B 44.25B 3.38B 3.31B 142B | 1.29B 1.14B 1.07B 972M 1.83B 124B 1.85B 12.91B 5B 63.2B 4.83B 4.72B 203B |
| Net Debt | -3.03B -2.7B -2.52B -2.29B -4.33B -292B -4.37B -30.45B -11.8B -149B -11.39B -11.15B -479B | -4.81B -4.27B -3.98B -3.63B -6.85B -462B -6.91B -48.22B -18.69B -236B -18.04B -17.65B -758B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | US$219.72 | -4.96% | 1,661,854 |
| 26-10-01 | US$231.18 | -6.31% | 2,017,406 |
| 26-09-30 | US$246.74 | -2.89% | 1,044,414 |
| 26-09-29 | US$254.07 | -0.51% | 787,081 |
| 26-09-28 | US$255.36 | -0.23% | 1,147,872 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
